NMDA Receptor (NMDAR) activity has been strongly implicated in both in-vitro and in-vivo learning models and the decline in cognitive function associated with aging and is linked to a decrease in NMDAR functional expression. GLYX-13 is a tetrapeptide (Thr-Pro-Pro-Thr) which Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Disclosure Statements
(a)Joseph Moskal is the inventor of the Glyxin family of neuropeptides of which GLYX-13 is one. He is a cofounder and stock holder in Naurex, Inc. Naurex, Inc. owns the Intellectual Property for GLYX-13. There are no financial, personal or other relationships with other people or organizations that could result in an actual or perceived conflict of interest by any other authors of this manuscript. That is there were no consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, grants or other funding to any of the coauthors. Coauthors Disterhoft and Stanton were paid a fee as consultants for overseeing some of the experiments, data analysis and interpretation as described in the NIH grant used to fund these studies.
(b)There are no Institutional contracts relating to this research or any other organization that could stand to gain financially now or in the future.
(c)There are no agreements of any authors or their institutions that could be seen as involving a financial interest in this work.
2.The financial support for all of the experiments reported here came from NIMH grant 071932 to JRM.
3.The data contained in the manuscript being submitted have not been previously published, have not been submitted elsewhere and will not be submitted elsewhere while under consideration at Neurobiology of Aging.
4.Statements verifying that appropriate approval and procedures were used concerning human subjects and animals are included in the manuscript.
5.I verify that all authors have reviewed the contents of the manuscript being submitted, approve of its contents and validate the accuracy of the data.
NIH Public Access
NIH-PA Author ManuscriptNIH-PA Author Manuscript NIH-PA Author Manuscript acts as a NMDAR receptor partial agonist at the glycine site. GLYX-13 was administered to young adult (3 month old) and aged (27-32 month old) Fischer 344 X Brown Norway F1 rats (FBNF1), and behavioral learning tested in trace eyeblink conditioning (tEBC), a movable platform version of the Morris water maze (MWM), and alternating t-maze tasks. GLYX-13 (1 mg/kg i.v.) enhanced learning in both young adult and aging animals for MWM and alternating tmaze, and increased tEBC in aging rats. We previously showed ...